Immunology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065 USA.
J Immunother Cancer. 2017 May 16;5:41. doi: 10.1186/s40425-017-0244-3. eCollection 2017.
Tumor cells can be detected and cleared by lymphocytes in a process termed cancer immunosurveillance. However, the contributing cell types had not been fully characterized. Using oncogene-induced murine models of epithelial cancer, a recent study showed that cell transformation triggers expansion of tissue-resident lymphocytes derived from innate, T cell receptor (TCR) αβ and TCRγδ lineages. These type-1-like innate lymphoid cells (ILC1ls) and type 1 innate-like T cells (ILTC1s) share a gene expression program distinct from those of conventional lymphocytes, and exhibit cytolytic activities against tumor cells. Further deciphering such a tumor-elicited immunosurveillance mechanism may 1 day be harnessed for novel cancer immunotherapy.
肿瘤细胞可以被淋巴细胞检测和清除，这个过程被称为癌症免疫监视。然而，其贡献细胞类型尚未完全确定。最近的一项研究使用致癌基因诱导的上皮癌小鼠模型表明，细胞转化触发了先天、T 细胞受体（TCR）αβ 和 TCRγδ 谱系的组织驻留淋巴细胞的扩增。这些 1 型样固有淋巴细胞（ILC1ls）和 1 型固有样 T 细胞（ILTC1s）与传统淋巴细胞的基因表达程序不同，并对肿瘤细胞表现出细胞毒性活性。进一步解析这种肿瘤诱导的免疫监视机制，有朝一日可能会被用于新型癌症免疫疗法。
